Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 12, 2013, Pages 7424-7430

  Milani, Behrad Y ^a   Milani, Farnoud Y ^a   Park, Dong wouk ^a   Namavari, Abed ^a   Shah, Jarna ^a   Amirjamshidi, Hossein ^a   Ying, Hongyu ^a   Djalilian, Ali R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Corneal haze; Excimer laser; Rapamycin

Indexed keywords

RAPAMYCIN; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORNEAL SCARRING; EXCIMER LASER; FEMALE; FIBROBLAST; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MYOFIBROBLAST; NONHUMAN; PHOTOREFRACTIVE KERATECTOMY; PRIORITY JOURNAL; RABBIT; RADIOIMMUNOPRECIPITATION; SCAR FORMATION; WESTERN BLOTTING;

CORNEAL HAZE; EXCIMER LASER; RAPAMYCIN;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CICATRIX; CORNEAL OPACITY; CORNEAL STROMA; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOFIBROBLASTS; PHOTOREFRACTIVE KERATECTOMY; RABBITS; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84887830444     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12674     Document Type: Article

References (36)

1. Birk DE, Trelstad RL. Extracellular compartments in matrix morphogenesis: collagen fibril, bundle, and lamellar formation by corneal fibroblasts. J Cell Biol. 1984; 99: 2024-2033.
2. Freegard TJ. The physical basis of transparency of the normal cornea. Eye (Lond). 1997; 11(Pt 4): 465-471.
3. Wilson SE. Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency. Exp Eye Res. 2012; 99: 78-88.
4. Wilson SE, Mohan RR, Netto M, et al. RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. Invest Ophthalmol Vis Sci. 2004; 45: 2201-2211.
5. Barbosa FL, Chaurasia SS, Cutler A, et al. Corneal myofibroblast generation from bone marrow-derived cells. Exp Eye Res. 2010; 91: 92-96.
6. Netto MV, Mohan RR, Sinha S, Sharma A, Gupta PC, Wilson SE. Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg. 2006; 22: 562-574.
7. Lichtinger A, Peer J, Frucht-Pery J, Solomon A. Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. Ophthalmology. 2010; 117: 431-437.
8. Dudney BW, Malecha MA. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival corneal intraepithelial neoplasia. Am J Ophthalmol. 2004; 137: 950-951.
9. Sauder G, Jonas JB. Limbal stem cell deficiency after subconjunctival mitomycin C injection for trabeculectomy. Am J Ophthalmol. 2006; 141: 1129-1130.
10. Ditta LC, Shildkrot Y, Wilson MW. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology. 2011; 118: 1754-1759.
11. Salomão DR, Mathers WD, Sutphin JE, Cuevas K, Folberg R. Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. Ophthalmology. 1999; 106: 1756-1760.
12. Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea. 1996; 15: 537-540.
13. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28: 721-726.
14. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12: 21-35.
15. Yoshizaki A, Yanaba K, Yoshizaki A, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycininduced mouse models of systemic sclerosis. Arthritis Rheum. 2010; 62: 2476-2487.
16. Zhu J, Wu J, Frizell E, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology. 1999; 117: 1198-1204.
17. Lee KS, Ko DA, Kim ES, Kim MJ, Tchah H, Kim JY. Bevacizumab and rapamycin can decrease corneal opacity and apoptotic keratocyte number following photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2012; 53: 7645-7653.
18. Shin YJ, Hyon JY, Choi WS, et al. Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-b1/ERK pathways regulation. Invest Ophthalmol Vis Sci. 2013; 54: 4452-4458.
19. Shi W, Gao H, Xie L, Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci. 2006; 47: 3339-3344.
20. Zapata G, Racca L, Tau J, Berra A. Topical use of rapamycin in herpetic stromal keratitis. Ocul Immunol Inflamm. 2012; 20: 354-359.
21. Shafiq MA, Gemeinhart RA, Yue BY, Djalilian AR. Decellularized human cornea for reconstructing the corneal epithelium and anterior stroma. Tissue Eng Part C Methods. 2012; 18: 340-348.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63.
23. Zhu X, Li L, Zou L, et al. A novel aptamer targeting TGF-b receptor II inhibits transdifferentiation of human tenon's fibroblasts into myofibroblast. Invest Ophthalmol Vis Sci. 2012; 53: 6897-6903.
24. Rasband WS. ImageJ. Bethesda, MD: U. S. National Institutes of Health; 1997-2012. Available at http://imagej. nih. gov/ij/.
25. Fantes FE, Hanna KD, Waring GO 3rd, Pouliquen Y, Thompson KP, Savoldelli M. Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. Arch Ophthalmol. 1990; 108: 665-675.
26. You L, Kruse FE. Differential effect of activin A and BMP-7 on myofibroblast differentiation and the role of the Smad signaling pathway. Invest Ophthalmol Vis Sci. 2002; 43: 72-81.
27. Tandon A, Tovey JC, Sharma A, Gupta R, Mohan RR. Role of transforming growth factor Beta in corneal function, biology and pathology. Curr Mol Med. 2010; 10: 565-578.
28. Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR. Trichostatin a inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci. 2009; 50: 2695-2701.
29. Dalle Pezze P, Sonntag AG, Thien A, et al. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation. Sci Signal. 2012; 5: ra25.
30. He J, Bazan HE. Epidermal growth factor synergism with TGFbeta1 via PI-3 kinase activity in corneal keratocyte differentiation. Invest Ophthalmol Vis Sci. 2008; 49: 2936-2945.
31. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22: 159-168.
32. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009; 8: 1026-1029.
33. Dugel PU, Blumenkranz MS, Haller JA, et al. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology. 2012; 119: 124-131.
34. Sen HN, Larson TA, Meleth AD, Smith WM, Nussenblatt RB. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial. Am J Ophthalmol. 2012; 153: 1038-1042.
35. Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013; 3: 32.
36. Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001; 213: 25-29.